Tag: WRAPSODY
WAVE trial reports Wrapsody superiority over standard PTA
Six-month results of the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial have reported superior target lesion primary patency (TLPP) with Wrapsody (Merit Medical) cell-impermeable...
Merit Medical’s Wrapsody WAVE trial demonstrates superior patency versus standard of...
Merit Medical has today announced positive six-month findings from the randomised arteriovenous (AV) fistula arm of its Wrapsody Arteriovenous Access Efficacy (WAVE) pivotal trial....
WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study completes enrolment
Merit Medical has announced that is has completed enrolment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective,...
First patient enrolled in Merit Medical’s WRAPSODY registry study
Merit Medical has announced the successful enrolment of the first patient in its WRAP registry study in a press release. This study will evaluate...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
First-in-human study of Wrapsody cell-impermeable endoprosthesis yields “very promising” results
Merit Medical Systems has announced positive results from a prospective, observational, first-in-human study to evaluate the safety and effectiveness of Wrapsody—a self-expanding, cell-impermeable endoprosthesis...
